Lipotype and Lund University publish about lipid profiles in Diabetes and infarction

Julia Schoener December 8, 2016

In the latest issue of the Journal of the American Heart Association, Lipotype and Lund University published a paper in which high-throughput lipidomic screening was successfully applied to reveal molecular lipid profiles in blood serum specific for Diabetes mellitus and myocardial infarction.

Read the whole publication here:

Identification of Shared and Unique Serum Lipid Profiles in Diabetes Mellitus and Myocardial Infarction, Journal of the American Heart Association, 2016
Sanela Kjellqvist, Christian Klose, Michal A. Surma, George Hindy, Inês G. Mollet, Anna Johansson, Patrick Chavaux, Johan Gottfries, Kai Simons, Olle Melander and Céline Fernandez

Publication, Academia, Biomarker

A new publication

Jeongeun Chae March 4, 2022

As a pioneer in the field of lipidomics, Lipotype not only provides lipidomic analysis services to customers but also contributes to science through carrying out its own research.

Lipidomics of Multiple Sclerosis

Henri Deda February 4, 2021

In multiple sclerosis (MS), a chronic inflammatory and neurodegenerative disease of the central nervous system, the body attacks the protective myelin sheath of neurons in the brain and the spinal cord. The damaged myelin causes communication problems between the central nervous system and the rest of the body. To this day, there is no cure for MS. Neurobiological researchers believe that MS does not only cause the clinical symptoms we look for as of today but also alters a patient’s lipid metabolism.

Multiomics analysis in CVD research

Henri Deda January 15, 2021

With an ever-increasing pool of accessible information and new tools to mine huge data sets, biology and medicine are moving from intervention to prevention. Omics sciences such as genomics and lipidomics are strong contributors to this paradigm shift. Being major players in cardiovascular disease research, genomics and lipidomics make a great multiomics pair. It matches the capacity to identify genetic predestinations with one or multiple snapshots of the lipid metabolic status to investigate cardiovascular diseases.